A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Lymphoma, Non-Hodgkin
Mantle Cell Lymphoma
Bladder Cancer
Uveal Melanoma, Recurrent
Cervix Cancer
Carcinoma in Situ
Head and Neck Squamous Cell Carcinoma
Skin Cancer
Metastatic Cancer
Tumor, Solid
Tumor Recurrence

Interventions

DRUG: ONM-501
DRUG: Cemiplimab

Sponsor

OncoNano Medicine, Inc.